TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30978268

Group type: EXPERIMENTAL
Intervention: Chewing gum (GG) three times per day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chewing gum (GG)
Number of subjects: 75
Study: 28601003

Group type: COMPARATOR
Intervention: Usual care (RT1) - moderate intensity (50% 1‐repetition maximum), low volume
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Higher intensity (RT2) - higher intensity (75% 1‐RM) and higher volume
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Moderate intensity but higher volume (RT3)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined aerobic training (AT) and resistance training (RT)
Number of subjects: 62
Study: 26711822

Group type: EXPERIMENTAL
Intervention: MIS‐TLIF using a tubular retraction system
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional TLIF
Number of subjects: 96
Study: 23339584

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) - up to 12 sessions in addition to usual care
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 36
Study: 16984012

Group type: EXPERIMENTAL
Intervention: Org 9426 (0.6 mg x kg(‐1))
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Org 9426 (0.9 mg x kg(‐1))
Number of subjects: 88

Group type: COMPARATOR
Intervention: Vecuronium (0.1 mg x kg(‐1))
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Org 9426 (0.15 mg x kg(‐1))
Number of subjects: 88
Study: 12580930

Group type: EXPERIMENTAL
Intervention: Acipimox/GHRH test
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GHRH/arginine test
Number of subjects: 35

Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Acipimox/GHRH test in controls
Number of subjects: 35

Group type: COMPARATOR
Intervention: Correlation with ITT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Correlation with GHRH/arginine test
Number of subjects: 35
Study: 10754734

Group type: EXPERIMENTAL
Intervention: Endoventricular plasty with patch (group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Endoventricular plasty without patch (group B)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (A and B) after surgery
Number of subjects: 33
Study: 7739102

Group type: EXPERIMENTAL
Intervention: Midazolam-famotidine suppository (0.5 mg.kg‐1 midazolam and 2 mg.kg‐1 famotidine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intramuscular injection of hydroxyzine (1 mg.kg‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Midazolam-famotidine suppository
Number of subjects: 45
Study: 1784664

Group type: EXPERIMENTAL
Intervention: ALCOHOL label
Number of subjects: 60

Group type: COMPARATOR
Intervention: WATER label
Number of subjects: 60

Group type: COMPARATOR
Intervention: NOT ALCOHOL label
Number of subjects: 60
Study: 6908098

Group type: EXPERIMENTAL
Intervention: Contingency contracting
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 115

Group type: COMPARATOR
Intervention: Routine clinic care
Number of subjects: 115
Study: 31838445

Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarette (8 mg/mL nicotine concentration)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Nicotine‐free e‐cigarettes (placebo)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study: 29532718

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin fluorouracil followed by conventional radiotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional radiotherapy with concurrent cisplatin
Number of subjects: 71
Study: 28599833

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25493968

Group type: EXPERIMENTAL
Intervention: Protocolized sedation plus daily sedation interruption
Number of subjects: 430

Group type: COMPARATOR
Intervention: Protocolized sedation
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Delirium screening positive patients
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Delirious patients
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Antecedent factors associated with delirium onset
Number of subjects: 430
Study: 23319256

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 245

Group type: COMPARATOR
Intervention: 3D conformal radiotherapy (3DCRT)
Number of subjects: 245
Study: 21995376

Group type: EXPERIMENTAL
Intervention: Xylitol gum for 3 months (from months 6 to 9)
Number of subjects: 248
Study: 18555546

Group type: EXPERIMENTAL
Intervention: Accelerated whole brain irradiation (40 Gy in 20 fractions of 2 Gy twice daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional whole brain irradiation (20 Gy in 5 daily fractions)
Number of subjects: 90
Study: 15990738

Group type: EXPERIMENTAL
Intervention: High-dose glucose-insulin-potassium (GIK) infusion
Number of subjects: 1044

Group type: COMPARATOR
Intervention: No infusion (control)
Number of subjects: 1044
Study: 14504153

Group type: EXPERIMENTAL
Intervention: 36 ml of mepivacaine 10 mg x ml(‐1)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 28 ml of mepivacaine 10 mg x ml(‐1)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 20 ml of mepivacaine 10 mg x ml(‐1)
Number of subjects: 114
Study: 10389555

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine and hyaluronidase 75 units/ml
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1:1 mixture of 2% lignocaine and 0.5% bupivacaine and hyaluronidase 75 units/ml
Number of subjects: 100
Study: 8906404

Group type: EXPERIMENTAL
Intervention: Generic perceptual memory retrieval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recollective memory retrieval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor-declarative memory retrieval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rote-declarative memory retrieval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-declarative memory retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semantic memory retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motor skill memory retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rote skill memory retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive skill memory retrieval
Number of subjects: 0
Study: 1867082

Group type: EXPERIMENTAL
Intervention: Single dose treatment with trimethoprim
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5-day course treatment with trimethoprim
Number of subjects: 100
Study: 6125193

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg)
Number of subjects: 0
Study: 29199193

Group type: EXPERIMENTAL
Intervention: Virtual reality program using Armeo® spring for 45 min three times/week for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy program
Number of subjects: 40
Study: 25647753

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 24329850

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study: 23106658

Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (2500 ova, 3 weekly doses over 6 months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Number of subjects: 89
Study: 19715417

Group type: EXPERIMENTAL
Intervention: Acyclovir (400 mg 3 times daily for 5 days)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study: 17559753

Group type: EXPERIMENTAL
Intervention: Tramadolor (200 mg, test formulation)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ultram ER (200 mg, reference formulation)
Number of subjects: 48
Study: 15124243

Group type: EXPERIMENTAL
Intervention: ACR 20
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ACR 50
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Average number of ACR criteria met at 50% level
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Area under the curve of ACR criteria met
Number of subjects: 6
Study: 12038917

Group type: EXPERIMENTAL
Intervention: Low reporting quality trials (median score, 9 [range, 3.5-10.5])
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High reporting quality trials (median score, 18 [range 16.5-22.0])
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: On-treatment analyses
Number of subjects: 60
Study: 9533973

Group type: EXPERIMENTAL
Intervention: Fluoxetine or Doxepin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nonresponse group (Fluoxetine or Doxepin)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 14
Study: 7898332

Group type: EXPERIMENTAL
Intervention: Aerobic exercise 45 min.d-1, 5 d.wk-1, for 12 wk
Number of subjects: 100
Study: 2796855

Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, doxorubicin and prednisone (VAP), consolidation therapy with 6‐thioguanine, cytosine arabinoside (TA) and cyclophosphamide/vincristine/cytosine arabinoside/prednisone (COAP), and maintenance therapy of alternating TA and COAP with or without VAP pulses.
Number of subjects: 0
Study: 872608

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 21

Group type: COMPARATOR
Intervention: Senna
Number of subjects: 21
Study: 31541495

Group type: EXPERIMENTAL
Intervention: HPV16/18 infection with borderline/low-grade cytology
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: HPV16/18 infection with normal cytology
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Other HPV types with borderline/low-grade cytology
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Other HPV types with normal cytology
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: New HPV infection with normal to low-grade cytology
Number of subjects: 379
Study: 31239021

Group type: EXPERIMENTAL
Intervention: 3-month behavioral weight loss (BWL) intervention
Number of subjects: 99
Study: 28521717

Group type: EXPERIMENTAL
Intervention: Antiretroviral regimens (specific regimens not detailed)
Number of subjects: 1771
Study: 25993906

Group type: EXPERIMENTAL
Intervention: Local trial - inhalation of a hypercapnic gas mixture (5% CO2 in air) for 5 minutes with open circulation to active calf muscle, followed by PECO.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic trial - circulation through the muscle closed throughout exercise and PECO phases during hypercapnic gas inhalation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperoxia trial - inhalation of a hyperoxic hypercapnic gas mixture (95% O2 and 5% CO2) for 1 minute during PECO under systemic conditions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of Local and Systemic trials.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of Systemic and Hyperoxia trials.
Number of subjects: 0
Study: 23881421

Group type: EXPERIMENTAL
Intervention: Grape seed extract (100 mg capsules three times daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no GSE)
Number of subjects: 30
Study: 21814146

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) supplementation (3 billion colony forming units/day for 21 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) supplementation
Number of subjects: 61
Study: 19489894

Group type: EXPERIMENTAL
Intervention: SAAF program participation
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 641
Study: 16956622

Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity (AS)
Number of subjects: 404
Study: 15028823

Group type: EXPERIMENTAL
Intervention: 10 mg of alendronate daily for 10 years
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: 5 mg of alendronate daily
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Discontinuation of alendronate
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo after discontinuation
Number of subjects: 247
Study: 12572052

Group type: EXPERIMENTAL
Intervention: Artemether combined with primaquine (Group A: orally, Group B: intramuscularly)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Single artemether (Group C: orally, Group D: intramuscularly)
Number of subjects: 121
Study: 9124619

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8129541

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg SL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg SL
Number of subjects: 20
Study: 3083459

Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg/70 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg/70 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg/70 kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31571403

Group type: EXPERIMENTAL
Intervention: Combination of mirabegron 50 mg/d plus solifenacin 5 mg/d
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Combination of mirabegron 50 mg/d plus propiverine 20 mg/d
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Combination of mirabegron 50 mg/d plus imidafenacin 0.2 mg/d
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Combination of mirabegron 50 mg/d plus tolterodine 4 mg/d
Number of subjects: 647

Group type: COMPARATOR
Intervention: All groups (including mirabegron 50 mg once daily during screening)
Number of subjects: 647
Study: 29435899

Group type: EXPERIMENTAL
Intervention: Drain placement
Number of subjects: 5013
Study: 26395781

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with general therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: General therapy (antibiotics only)
Number of subjects: 0
Study: 24942709

Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/d)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 22166162

Group type: EXPERIMENTAL
Intervention: Calcium sulfate (CS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Freeze-dried bone allograft (FDBA)
Number of subjects: 31
Study: 20378678

Group type: EXPERIMENTAL
Intervention: Functional Training + Balance program (FT+B)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Functional Training program (FT)
Number of subjects: 43
Study: 18340272

Group type: COMPARATOR
Intervention: Electric stimuli delivered to the right median nerve (Con 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory stimuli delivered to both ears (Con 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electric and subsequent auditory stimuli (Con 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electric stimuli delivered to the bilateral median nerve (Con 4)
Number of subjects: 0
Study: 15795210

Group type: EXPERIMENTAL
Intervention: Changing gloves at 20-minute intervals or prior to cementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Changing gloves prior to cementation
Number of subjects: 50
Study: 12351954

Group type: EXPERIMENTAL
Intervention: Multivitamins excluding A
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 1078
Study: 10064647

Group type: EXPERIMENTAL
Intervention: Propofol sandwich anesthetic (PSAND)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Total propofol anesthesia (TPROP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Inhalational anesthesia (INHAL)
Number of subjects: 120
Study: 7769295

Group type: EXPERIMENTAL
Intervention: Vaccine adjuvanted with alum
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vaccine adjuvanted with alum plus 3-deacylated monophosphoryl lipid A (MPL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both formulations (alum and alum-MPL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MPL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protected subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 protected subject
Number of subjects: 20
Study: 2284521

Group type: EXPERIMENTAL
Intervention: Metronidazole pessaries (500 mg, once daily for 7 days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 94616

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moduretic (50 mg hydrochlorothiazide and 5 mg amiloride)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 20
Study: 6195479

Group type: EXPERIMENTAL
Intervention: NTG after 1 g of oral aspirin pretreatment
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: NTG after 8 days of aspirin, 500 mg every 48 h
Number of subjects: 7

Group type: COMPARATOR
Intervention: NTG without aspirin pretreatment
Number of subjects: 7
Study: 31138568

Group type: EXPERIMENTAL
Intervention: ASN100 (combination of ASN‐1 and ASN‐2) at 3,600 or 8,000 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ASN100 (combination of ASN‐1 and ASN‐2)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ASN‐1 or ASN‐2 at 200, 600, 1,800, or 4,000 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Open-label ASN100 at 3,600 or 8,000 mg
Number of subjects: 52
Study: 29563100

Group type: EXPERIMENTAL
Intervention: Tai chi (12 or 24 weeks, once or twice weekly)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Tai chi (24 weeks, twice weekly)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Tai chi (24 weeks)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Aerobic exercise (24 weeks, twice weekly)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Tai chi (various groups)
Number of subjects: 226
Study: 26909531

Group type: EXPERIMENTAL
Intervention: Culturally based exercise (Bhangra dance)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Standard exercise (gym‐based)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (nonexercise)
Number of subjects: 75
Study: 25287629

Group type: EXPERIMENTAL
Intervention: E-RS (EXACT - Respiratory Symptoms) scale
Number of subjects: 1581
Study: 22377744

Group type: EXPERIMENTAL
Intervention: Oral theophylline at daily doses of 200, 300, 400, 600, and 800 mg for periods of 2‐10 months
Number of subjects: 23
Study: 19833819

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Carboplatin (GC)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Paclitaxel (GP)
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Paclitaxel + Carboplatin (PC)
Number of subjects: 1135
Study: 18055944

Group type: EXPERIMENTAL
Intervention: Amisulpride plus needs-focused intervention
Number of subjects: 124

Group type: COMPARATOR
Intervention: Needs-focused intervention without amisulpride
Number of subjects: 124
Study: 16131623

Group type: EXPERIMENTAL
Intervention: Bimodal detection task with auditory signal (1000-Hz tone) and visual signal (asterisk)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bimodal detection task
Number of subjects: 0
Study: 11861971

Group type: EXPERIMENTAL
Intervention: Chlorpyrifos (CPF) administered orally at doses of 0.5-100 mg/kg in rats and 0.5-2 mg/kg in humans.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Chlorpyrifos (CPF)
Number of subjects: 2
Study: 9435424

Group type: EXPERIMENTAL
Intervention: GHRP‐1 (100-micrograms i.v. bolus)
Number of subjects: 68
Study: 7823066

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 243

Group type: COMPARATOR
Intervention: All drugs
Number of subjects: 243
Study: 1977464

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg bd
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg bd
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 40798

Group type: EXPERIMENTAL
Intervention: metoprolol 10, 40 or 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: alprenolol 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: no beta-blockade (control)
Number of subjects: 12
Study: 31671219

Group type: EXPERIMENTAL
Intervention: Biomarkers associated with increased ESCC risk (FGF19, ST1A1, STAMBP, AXIN1, CASP8, NT3, CD6, CDCP1, CD5, SLAMF1, OPG, CSF1)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Biomarkers inversely associated with ESCC risk (CXCL6, CCL23, CXCL5, TGFA, CXCL1, OSM, CCL4)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Statistically significant biomarkers (FGF19, CASP8, STAMBP, ST1A1, CCL-4)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Correlation among biomarkers (CASP8, STAMBP, ST1A1)
Number of subjects: 476
Study: 30970113

Group type: EXPERIMENTAL
Intervention: X technique (6 repetitions)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: X technique (3 repetitions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no systematized guidelines)
Number of subjects: 30
Study: 28283805

Group type: EXPERIMENTAL
Intervention: Stress management intervention (eight sessions)
Number of subjects: 74
Study: 25734979

Group type: EXPERIMENTAL
Intervention: 12 month screener based on Bayley Scales of Infant Development II
Number of subjects: 0
Study: 25031380

Group type: EXPERIMENTAL
Intervention: Continuous passive motion device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standardized physical therapy
Number of subjects: 40
Study: 22914044

Group type: EXPERIMENTAL
Intervention: TPVB
Number of subjects: 153

Group type: COMPARATOR
Intervention: CWC
Number of subjects: 153

Group type: COMPARATOR
Intervention: PCA
Number of subjects: 153
Study: 19785568

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 857

Group type: COMPARATOR
Intervention: Simvastatin 20 mg/day
Number of subjects: 857

Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day
Number of subjects: 857
Study: 17207073

Group type: EXPERIMENTAL
Intervention: Topical capsaicin cream (0.075%) applied unilaterally to the mental area, four times daily for 2 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical capsaicin cream (0.075%)
Number of subjects: 20